SHANXI ZHENDONG PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.01 CNY | +6.60% |
|
+11.33% | -25.78% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,936 | 5,000 | 5,651 | 8,415 | 7,655 | 6,936 |
| Enterprise Value (EV) 1 | 3,508 | 4,421 | 5,164 | 3,041 | 4,937 | 4,690 |
| P/E ratio | -26.8 x | 35 x | 21.6 x | 3.22 x | -149 x | -158 x |
| Yield | - | 1.03% | 1.27% | 34.2% | - | - |
| Capitalization / Revenue | 1.15 x | 1.14 x | 1.17 x | 1.65 x | 2.05 x | 1.91 x |
| EV / Revenue | 1.03 x | 1 x | 1.07 x | 0.6 x | 1.32 x | 1.29 x |
| EV / EBITDA | 22.5 x | 14 x | 12.4 x | 11.2 x | 493 x | 264 x |
| EV / FCF | 13.9 x | 9.58 x | -18.7 x | 5.78 x | 45.2 x | -12 x |
| FCF Yield | 7.21% | 10.4% | -5.35% | 17.3% | 2.21% | -8.3% |
| Price to Book | 0.73 x | 0.92 x | 1 x | 1.04 x | 1.46 x | 1.34 x |
| Nbr of stocks (in thousands) | 1,033,055 | 1,033,055 | 1,027,495 | 1,027,495 | 1,027,495 | 1,027,495 |
| Reference price 2 | 3.810 | 4.840 | 5.500 | 8.190 | 7.450 | 6.750 |
| Announcement Date | 4/24/19 | 4/23/20 | 4/23/21 | 3/30/22 | 4/24/23 | 4/22/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 3,420 | 4,399 | 4,848 | 5,094 | 3,729 | 3,626 |
| EBITDA 1 | 155.9 | 315.1 | 416.6 | 271.1 | 10.02 | 17.77 |
| EBIT 1 | 42.97 | 199.7 | 251.9 | 147.4 | -114.5 | -99.52 |
| Operating Margin | 1.26% | 4.54% | 5.2% | 2.89% | -3.07% | -2.74% |
| Earnings before Tax (EBT) 1 | -87.09 | 191.4 | 322.9 | 3,116 | -5.28 | -37.69 |
| Net income 1 | -147.4 | 142.8 | 262 | 2,617 | -51.29 | -43.98 |
| Net margin | -4.31% | 3.25% | 5.41% | 51.38% | -1.38% | -1.21% |
| EPS 2 | -0.1424 | 0.1382 | 0.2550 | 2.547 | -0.0499 | -0.0428 |
| Free Cash Flow 1 | 253.1 | 461.2 | -276.4 | 526.2 | 109.1 | -389.2 |
| FCF margin | 7.4% | 10.49% | -5.7% | 10.33% | 2.93% | -10.73% |
| FCF Conversion (EBITDA) | 162.34% | 146.38% | - | 194.09% | 1,088.84% | - |
| FCF Conversion (Net income) | - | 323.06% | - | 20.11% | - | - |
| Dividend per Share | - | 0.0500 | 0.0700 | 2.800 | - | - |
| Announcement Date | 4/24/19 | 4/23/20 | 4/23/21 | 3/30/22 | 4/24/23 | 4/22/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 428 | 579 | 488 | 5,375 | 2,718 | 2,246 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 253 | 461 | -276 | 526 | 109 | -389 |
| ROE (net income / shareholders' equity) | -2.76% | 2.54% | 4.58% | 38.1% | -0.86% | -0.92% |
| ROA (Net income/ Total Assets) | 0.36% | 1.77% | 2.17% | 1.04% | -0.86% | -0.98% |
| Assets 1 | -40,708 | 8,079 | 12,080 | 251,338 | 5,964 | 4,501 |
| Book Value Per Share 2 | 5.190 | 5.260 | 5.490 | 7.860 | 5.110 | 5.040 |
| Cash Flow per Share 2 | 0.7000 | 0.4900 | 0.9000 | 1.190 | 0.7000 | 0.7800 |
| Capex 1 | 23.9 | 19.4 | 184 | 152 | 146 | 116 |
| Capex / Sales | 0.7% | 0.44% | 3.79% | 2.98% | 3.91% | 3.21% |
| Announcement Date | 4/24/19 | 4/23/20 | 4/23/21 | 3/30/22 | 4/24/23 | 4/22/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -30.37% | 667M | |
| +28.13% | 662B | |
| +22.02% | 546B | |
| -4.94% | 359B | |
| +16.98% | 323B | |
| +4.08% | 289B | |
| +13.68% | 234B | |
| +3.86% | 198B | |
| -10.31% | 194B | |
| +4.13% | 167B |
- Stock Market
- Equities
- 300158 Stock
- Financials Shanxi Zhendong Pharmaceutical Co.,Ltd